

Bernhard Engliger

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7037665/publications.pdf>

Version: 2024-02-01

19
papers

528
citations

840776

11
h-index

839539

18
g-index

19
all docs

19
docs citations

19
times ranked

1168
citing authors

#	ARTICLE	IF	CITATIONS
1	Fibroblast growth factor receptor 4 promotes glioblastoma progression: a central role of integrin-mediated cell invasiveness. <i>Acta Neuropathologica Communications</i> , 2022, 10, 65.	5.2	8
2	ETMR-12. Novel cell models of CNS tumors with BCOR fusion or internal tandem duplication suggest FGFR and PDGFR as promising therapy targets. <i>Neuro-Oncology</i> , 2022, 24, i52-i52.	1.2	0
3	Targeting fibroblast growth factor receptors to combat aggressive ependymoma. <i>Acta Neuropathologica</i> , 2021, 142, 339-360.	7.7	14
4	Non-viral gene delivery of the oncotoxic protein NS1 for treatment of hepatocellular carcinoma. <i>Journal of Controlled Release</i> , 2021, 334, 138-152.	9.9	3
5	Cerebrospinal fluid penetration of targeted therapeutics in pediatric brain tumor patients. <i>Acta Neuropathologica Communications</i> , 2020, 8, 78.	5.2	28
6	Lipid droplet-mediated scavenging as novel intrinsic and adaptive resistance factor against the multikinase inhibitor ponatinib. <i>International Journal of Cancer</i> , 2020, 147, 1680-1693.	5.1	16
7	Subcellular Duplex DNA and G-Quadruplex Interaction Profiling of a Hexagonal Pt II Metallacycle. <i>Angewandte Chemie</i> , 2019, 131, 8091-8096.	2.0	10
8	Subcellular Duplex DNA and G-Quadruplex Interaction Profiling of a Hexagonal Pt ^{II} Metallacycle. <i>Angewandte Chemie - International Edition</i> , 2019, 58, 8007-8012.	13.8	39
9	Metal Drugs and the Anticancer Immune Response. <i>Chemical Reviews</i> , 2019, 119, 1519-1624.	47.7	237
10	Design, synthesis, nuclear localization, and biological activity of a fluorescent duocarmycin analog, HxTfA. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2018, 28, 1342-1347.	2.2	5
11	Biological activity of PtIV prodrugs triggered by riboflavin-mediated bioorthogonal photocatalysis. <i>Scientific Reports</i> , 2018, 8, 17198.	3.3	24
12	Lysosomal Sequestration Impairs the Activity of the Preclinical FGFR Inhibitor PD173074. <i>Cells</i> , 2018, 7, 259.	4.1	8
13	Nanoformulations of anticancer FGFR inhibitors with improved therapeutic index. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2018, 14, 2632-2643.	3.3	22
14	Altered membrane rigidity via enhanced endogenous cholesterol synthesis drives cancer cell resistance to destruxins. <i>Oncotarget</i> , 2018, 9, 25661-25680.	1.8	14
15	The Natural Fungal Metabolite Beauvericin Exerts Anticancer Activity In Vivo: A Pre-Clinical Pilot Study. <i>Toxins</i> , 2017, 9, 258.	3.4	22
16	Intrinsic fluorescence of the clinically approved multikinase inhibitor nintedanib reveals lysosomal sequestration as resistance mechanism in FGFR-driven lung cancer. <i>Journal of Experimental and Clinical Cancer Research</i> , 2017, 36, 122.	8.6	33
17	CD44 drives aggressiveness and chemoresistance of a metastatic human osteosarcoma xenograft model. <i>Oncotarget</i> , 2017, 8, 114095-114108.	1.8	18
18	Acquired nintedanib resistance in FGFR1-driven small cell lung cancer: role of endothelin-A receptor-activated ABCB1 expression. <i>Oncotarget</i> , 2016, 7, 50161-50179.	1.8	19

#	ARTICLE	IF	CITATIONS
19	Chronic arsenic trioxide exposure leads to enhanced aggressiveness via Met oncogene addiction in cancer cells. <i>Oncotarget</i> , 2016, 7, 27379-27393.	1.8	8